Eribulin Mesylate*
-
API Product :
Eribulin Mesylate*
-
CEP :
-
-
WCC :
-
-
Therapeutic Use :
Anticancer
-
Originator :
Eisai
-
CAS No. :
253128-41-5
-
Trade Name. :
Halaven
-
Molecular Weight :
729.90 g/mol
-
Molecular Formula :
C40H59NO11
Application
Eribulin mesylate is approved to treat: Breast cancer that has metastasized (spread to other parts of the body). It is used in patients who have already been treated with an anthracycline and a taxane.
General Description
Eribulin is an anticancer drug marketed by Eisai Co. under the trade name Halaven. Eribulin is also known as E7389 and ER-086526, and also carries the US NCI designation NSC-707389. It is used to treat certain patients with breast cancer and liposarcoma.